CAQK Peptide-Modified Quercetin Nanoparticles Improve TBI Prognosis by Inhibiting Aberrant Nrf2-Keap1 Signaling
Background
Traumatic brain injury (TBI) is a leading cause of mortality and disability, with secondary injury representing a critical therapeutic target. Current treatments often fall short due to the complex and heterogeneous nature of TBI, which involves hyperacute excitotoxic bursts, acute apoptotic events, and blood-brain barrier failure. Quercetin (QR), a natural flavonoid, shows promise due to its antioxidant and anti-inflammatory properties, primarily through modulating the Nrf2-Keap1 pathway. However, its poor blood-brain barrier (BBB) permeability and low bioavailability severely limit its brain-targeted delivery and clinical utility.
Study Design
Researchers developed CAQK peptide-modified, reactive oxygen species (ROS)-responsive nanoparticles (C-PPS/Q), utilizing PPS120 as a core for targeted Quercetin delivery. In vitro, they assessed C-PPS/Q's ROS-triggered Quercetin release, HT22 cell uptake, and effects on ROS levels and apoptosis. In vivo, a TBI mouse model was used to evaluate C-PPS/Q's accumulation at the lesion site, Quercetin half-life, biocompatibility, impact on BBB integrity, neuroinflammation, Nrf2-Keap1 pathway activation, and neurological function. The abstract does not specify the number of animals, dose, route, frequency, or duration of treatment.
Results
The engineered C-PPS/Q nanoparticles demonstrated ROS-triggered Quercetin release, leading to significantly enhanced HT22 cell uptake in vitro. This enhanced delivery resulted in reduced ROS levels and apoptosis in cell models. In the TBI mouse model, C-PPS/Q exhibited specific accumulation at the lesion site, prolonging the half-life of Quercetin. The nanoparticles also showed excellent biocompatibility and preserved BBB integrity. Crucially, C-PPS/Q attenuated neuroinflammation and inhibited aberrant Nrf2-Keap1 pathway activation. This multifaceted action culminated in a markedly improved neurological function in the treated mice. The abstract does not provide specific quantitative data (e.g., percentages, p-values, fold-changes) for these improvements. However, the overall impact was clear:
C-PPS/Qnanoparticles effectively mitigate secondary brain injury after TBI and represent a promising brain-targeted therapeutic strategy.
Key Findings
- CAQK peptide-modified, ROS-responsive nanoparticles (C-PPS/Q) achieved targeted Quercetin delivery.
- C-PPS/Q nanoparticles exhibited ROS-triggered Quercetin release and enhanced
HT22cell uptakein vitro. - C-PPS/Q reduced
ROSlevels and apoptosis in cell models. - In a TBI mouse model, C-PPS/Q specifically accumulated at the lesion site and prolonged Quercetin's half-life.
- C-PPS/Q preserved BBB integrity, attenuated neuroinflammation, and markedly improved neurological function in TBI mice.
Why It Matters
This research offers a novel strategy for brain-targeted delivery of therapeutic compounds like Quercetin, overcoming a major hurdle for many neuroprotective agents: the blood-brain barrier. For individuals with TBI, this could pave the way for more effective interventions that limit secondary injury and improve long-term outcomes. The use of ROS-responsive nanoparticles ensures drug release precisely where and when it's needed most, maximizing efficacy while minimizing systemic exposure. While still in preclinical stages, this approach highlights how advanced nanocarriers can unlock the full potential of natural compounds, potentially leading to future protocols that combine specific targeting peptides with controlled-release mechanisms for conditions like TBI.
traumatic-brain-injury
tbi
quercetin
nanoparticles
nrf2-keap1
neuroprotection